38821-53-3

• 常用中文名：头孢拉定
• 常用英文名：Cefradine
• CAS号：38821-53-3
• 分子式：C₁₆H₁₉N₃O₄S
• 分子量：349.405
• 相关类别： 原料药 抗生素类药物 头孢菌素类药
• 发布时间：2018-08-04 19:01:45
• 更新时间：2026-07-01 11:58:24
• Cefradine是第一代头孢类抗生素。
• 该品为广谱、高效、低毒抗生素，对革兰氏阳性及阴性菌均有杀菌作用。该品不受青毒素酶的影响，对大多数产生青霉素酶的金黄色葡萄球菌和大肠杆菌亦有显著活性。性状：该品为头孢拉定和精氨酸混和的白色或类白色粉末、易溶于水。

名称

• 中文名: 头孢拉定
• 英文名: cephradine
• 中文别名: 食品级富兰克胶(亚麻籽胶); 头孢拉定 口服级别(纯粉); 头孢拉定聚合物; 头孢拉定/用于峰鉴定试验/A1A; 先锋霉素Ⅵ; 头孢雷定; 塞发莱定; 头孢拉定,压实粉; 水溶头孢拉定; 头孢拉丁精胺酸盐; 头孢拉定(供注射用); 头孢拉定(标准品); 头孢拉定-头孢拉定双键位移杂质; 头孢环己烯; 头孢拉定,10 MM DMSO 溶液; 头孢拉定溶液,100PPM; (6R,7R)-7-[(R)-2-氨基-2-(1,4-环己二烯基)乙酰氨基]-3-甲基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸; 头孢拉定杂质; 头孢拉定(头孢拉定对照品); CHRADINE 头孢拉定级别,医药级别,细胞培养级); (6R,7R)-7-((R)-2-氨基-2-(环己-1,4-二烯-1-基)乙酰氨基)-3-甲基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛烷-2-烯-2-羧酸; 头孢拉定/A1A; 原料药头孢拉定; 食品级富兰克胶(亚麻籽胶)直销; 头孢瑞丁; 头抱拉定; 食品级富兰克胶(亚麻籽胶)作用; 头孢拉定 兽用级别; 头孢拉定检测标准品; 头孢拉定 标准品; 头孢拉丁; 头孢拉定杂质(7个); 头孢拉定一水合物; 头孢拉定 注射级别; 富兰克胶(亚麻籽胶); 头孢菌素Ⅵ; (6R,7R)-7-((R)-2-氨基-2-(1,4-环己二烯基)乙酰氨基)-3-甲基-8-氧代-5-硫杂-1-氮杂双环(4.2.0)辛-2-烯-2-甲酸; 头孢拉定 (含精氨酸); 头孢拉定峰鉴别 标准品; ANSPOR|||CHRADIN|||VELOSEF|||SQ-11436|||SEFRIL|||头孢拉定; (6R,7R)-7-((R)-2-氨基-2-(环己-1,4-二烯-1-基)乙酰胺)-3-甲基-8-氧代-5-噻-1-氮杂双环[4.2.0]辛-3-烯-2-羧酸 (头孢拉定杂质); 头孢环己烯、头孢菌素Ⅵ、头孢雷定、头孢瑞丁、先锋霉素Ⅵ; 富兰克胶(亚麻籽胶)作用
• 英文别名: 7-[D-a-Amino-(1,4-cyclohexadienyl)acetamide]-3-desacetoxychalosphoranic acid; Megacef; CHRADINE; Cefradine IMP; EINECS 254-137-8; Cefradine(non-sterile); (6R,7R)-7-[[2-amino-2-(1-cyclohexa-1,4-dienyl)-1-oxoethyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; Ecosporina; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[[(2R)-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methyl-8-oxo-, (6R,7R); icyclo[4.2.0]-oct-2-ene-2-caboxylicacid; Cefradine Impurity; Lenzacef; 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-cboxylicacid,7-((amino-1,4-cyclohexad; Cefradex; chradine(compacted)chradine(compacted); CEFRADIN; (6R-(6alpha,7))-((Amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic aci; Velocef; CHRADINE APPROX. (HPLC); Cefradin Cephradine; (6R-(6alpha,7))-((Amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Soluble Cefradine; Cefradine CRS; Dimacef; Cefradine Cefradine; MFCD01743037; Lisacef; 7-[-amino-2-(1,4-cyclohexadienyl)acetamide]desacetoxychalosporanicacid; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylicacid, 7-[[(2R)-2-amino-2-(1,4-cyclohexadien-1-yl)acetyl]amino]-3-Methyl-8-oxo-,(6R,7R); velosef; sefril; Cefro; chradin; Cefradine for peak identification CRS; CHRADINE MICRONISED POWDER; Chradine Monohydrate CoMpacted/Powder; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid, 7-[(amino-1,4-cyclohexadien-1-ylacetyl)amino]-3-methyl-8-oxo-, [6R-[6α,7β(R*)]]; Samedrin; (6r-(6-alpha,7-beta(r*)))-ien-1-ylacetyl)amino)-3-methyl-8-oxo; sq11436; CHRADINE Manufacturer 38-3 For Antibiotic; (6r-6alpha,7beta(r*)))-ien-1-ylacetyl)amino)-3-methyl-8-ox; 7-{[amino(cyclohexa-1,4-dien-1-yl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Chradine (base and/or unspecified salts); good quantity Cefradine; Chradine,Cefradin; Cefradine CAS # 38-3; 7-{[Amino(1,4-cyclohexadien-1-yl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CEFRADINE; Cefrag; (6R,7R)-7-[[(2R)-2-amino-2-(1,4-cyclohexadien-1-yl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic Acid; Anspor; eskacef; Chradine, >=; Cefril; (6r-(6alpha,7))-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-cboxylic acid; CHRADINE COMPACTED; Easkacef; The setting of the; Cesporan; Escacef; Cefradine API; CHRADINE HYDRATE; Cephradine; Cefradin,Cephradine; 7-[-amino-2-(1,4-cyclohexadien-1-yl)acetamido]-3-methyl-8-oxo-5-thia-1-azab

物化性质

• 密度: 1.5±0.1 g/cm3
• 沸点: 693.1±55.0 °C at 760 mmHg
• 熔点: 140-142ºC
• 分子式: C₁₆H₁₉N₃O₄S
• 分子量: 349.405
• 闪点: 373.0±31.5 °C
• 精确质量: 349.109619
• PSA: 138.03000
• LogP: 0.98
• 外观性状: 固体
• 蒸汽压: 0.0±4.7 mmHg at 25°C
• 折射率: 1.684
• 储存条件: Store at 0-5°C

生物活性

• 描述: Cefradine是第一代头孢类抗生素。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  研究领域 >> 感染

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XI0336000 CHEMICAL NAME : 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien- 1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))- CAS REGISTRY NUMBER : 38821-53-3 LAST UPDATED : 199612 DATA ITEMS CITED : 17 MOLECULAR FORMULA : C16-H19-N3-O4-S MOLECULAR WEIGHT : 349.44 WISWESSER LINE NOTATION : T46 AN ES GUTJ HVQ CMVYZ- AL6U DUTJ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 5 mg/kg TOXIC EFFECTS : Skin and Appendages - dermatitis, other (after systemic exposure) REFERENCE : CUTIBC CUTIS; Cutaneous Medicine for the Practitioner. (Technical Pub., 875 Third Ave., New York, NY NY 10022) 1965- Volume(issue)/page/year: 38,58,1986 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >12 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >7500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3549 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 597 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 8,680,1977 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2890 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 8,680,1977 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3539 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 8,680,1977 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 56 gm/kg/28D-I TOXIC EFFECTS : Kidney, Ureter, Bladder - urine volume increased Kidney, Ureter, Bladder - changes in bladder weight REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 3),131,1980 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 182 gm/kg/13W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 182 gm/kg/26W-I TOXIC EFFECTS : Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - other changes Endocrine - changes in adrenal weight REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 3 gm/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 600 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1200 mg/kg SEX/DURATION : female 7-12 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 23,37,1975 *** REVIEWS *** TOXICOLOGY REVIEW PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,279,1979 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3583 No. of Facilities: 258 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 4339 (estimated) No. of Female Employees: 1693 (estimated)

安全

• 符号: GHS07, GHS08
• 信号词: Danger
• 危害声明: H315-H317-H319-H334-H335
• 警示性声明: P261-P280-P284-P304 + P340-P305 + P351 + P338-P342 + P311
• 危害码 (欧洲): Xi:Irritant
• 风险声明 (欧洲): R36/37/38;R42/43
• 安全声明 (欧洲): S26-S36
• 危险品运输编码: NONH for all modes of transport
• RTECS号: XI0336000
• 海关编码: 2941905400

海关

海关编码	2941905400